| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2023-02-21 17:14:27 UTC |
|---|
| HMDB ID | HMDB0000017 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 4-Pyridoxic acid |
|---|
| Description | 4-Pyridoxic acid is a member of the class of compounds known as methylpyridines. More specifically it is a 2-methylpyridine derivative substituted by a hydroxy group at C-3, a carboxy group at C-4, and a hydroxymethyl group at C-5. 4-Pyridoxic acid is the catabolic product of vitamin B6 (also known as pyridoxine, pyridoxal and pyradoxamine) and is excreted in the urine. Urinary levels of 4-pyridoxic acid are lower in females than in males and will be reduced even further in persons with a riboflavin deficiency. 4-Pyridoxic acid is formed by the action of aldehyde oxidase I (an endogenous enzyme) and by microbial enzymes (pyridoxal 4-dehydrogenase), an NAD-dependent aldehyde dehydrogenase. 4-pyridoxic acid can be further broken down by the gut microflora via the enzyme known as 4-pyridoxic acid dehydrogenase. This enzyme catalyzes the four-electron oxidation of 4-pyridoxic acid to 3-hydroxy-2-methylpyridine-4,5-dicarboxylate, using nicotinamide adenine dinucleotide (NAD) as a cofactor. |
|---|
| Structure | CC1=NC=C(CO)C(C(O)=O)=C1O InChI=1S/C8H9NO4/c1-4-7(11)6(8(12)13)5(3-10)2-9-4/h2,10-11H,3H2,1H3,(H,12,13) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Methyl-3-hydroxy-4-carboxy-5-hydroxymethylpyridine | ChEBI | | 3-Hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxylic acid | ChEBI | | 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinic acid | ChEBI | | 4-Pyridoxinecarboxylic acid | ChEBI | | 4-Pyridoxinic acid | ChEBI | | 4-Pyridoxinsaeure | ChEBI | | 4-Pyridoxylic acid | ChEBI | | Pyridoxic acid | ChEBI | | 3-Hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxylate | Generator | | 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinate | Generator | | 4-Pyridoxinecarboxylate | Generator | | 4-Pyridoxinate | Generator | | 4-Pyridoxylate | Generator | | Pyridoxate | Generator | | 4-Pyridoxate | Generator | | 3-Hydroxy-5-(hydroxymethyl)-2-methyl-isonicotinate | HMDB | | 3-Hydroxy-5-(hydroxymethyl)-2-methyl-isonicotinic acid | HMDB | | 3-Hydroxy-5-hydroxymethyl-2-methyl-isonicotinate | HMDB | | 3-Hydroxy-5-hydroxymethyl-2-methyl-isonicotinic acid | HMDB | | 3-Hydroxy-5-hydroxymethyl-2-methyl-isonicotinsaeure | HMDB | | 4 Pyridoxinic acid | MeSH, HMDB | | Pyridoxinecarboxylic acid | MeSH, HMDB | | 4 Pyridoxylic acid | MeSH, HMDB | | 4 Pyridoxic acid | MeSH, HMDB |
|
|---|
| Chemical Formula | C8H9NO4 |
|---|
| Average Molecular Weight | 183.1614 |
|---|
| Monoisotopic Molecular Weight | 183.053157781 |
|---|
| IUPAC Name | 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxylic acid |
|---|
| Traditional Name | pyridoxic acid |
|---|
| CAS Registry Number | 82-82-6 |
|---|
| SMILES | CC1=NC=C(CO)C(C(O)=O)=C1O |
|---|
| InChI Identifier | InChI=1S/C8H9NO4/c1-4-7(11)6(8(12)13)5(3-10)2-9-4/h2,10-11H,3H2,1H3,(H,12,13) |
|---|
| InChI Key | HXACOUQIXZGNBF-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as pyridinecarboxylic acids. Pyridinecarboxylic acids are compounds containing a pyridine ring bearing a carboxylic acid group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Pyridines and derivatives |
|---|
| Sub Class | Pyridinecarboxylic acids and derivatives |
|---|
| Direct Parent | Pyridinecarboxylic acids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Pyridine carboxylic acid
- Hydroxypyridine
- Methylpyridine
- Vinylogous acid
- Heteroaromatic compound
- Azacycle
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic oxygen compound
- Hydrocarbon derivative
- Alcohol
- Aromatic alcohol
- Organic nitrogen compound
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxide
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 247 - 248 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 4337 mg/L @ 25 °C (est) | The Good Scents Company Information System | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.22 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.4742 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.96 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 129.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 489.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 294.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 67.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 161.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 40.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 247.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 297.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 319.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 603.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 40.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 921.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 179.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 189.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 602.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 314.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 425.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 4-Pyridoxic acid,1TMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C)C(C(=O)O)=C1O | 1856.0 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,1TMS,isomer #2 | CC1=NC=C(CO)C(C(=O)O[Si](C)(C)C)=C1O | 1837.4 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,1TMS,isomer #3 | CC1=NC=C(CO)C(C(=O)O)=C1O[Si](C)(C)C | 1805.1 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,2TMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)=C1O | 1875.8 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,2TMS,isomer #2 | CC1=NC=C(CO[Si](C)(C)C)C(C(=O)O)=C1O[Si](C)(C)C | 1831.9 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,2TMS,isomer #3 | CC1=NC=C(CO)C(C(=O)O[Si](C)(C)C)=C1O[Si](C)(C)C | 1863.9 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,3TMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)=C1O[Si](C)(C)C | 1952.4 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,1TBDMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(C(=O)O)=C1O | 2113.2 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,1TBDMS,isomer #2 | CC1=NC=C(CO)C(C(=O)O[Si](C)(C)C(C)(C)C)=C1O | 2099.9 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,1TBDMS,isomer #3 | CC1=NC=C(CO)C(C(=O)O)=C1O[Si](C)(C)C(C)(C)C | 2064.3 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,2TBDMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)=C1O | 2330.2 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,2TBDMS,isomer #2 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(C(=O)O)=C1O[Si](C)(C)C(C)(C)C | 2338.8 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,2TBDMS,isomer #3 | CC1=NC=C(CO)C(C(=O)O[Si](C)(C)C(C)(C)C)=C1O[Si](C)(C)C(C)(C)C | 2350.0 | Semi standard non polar | 33892256 | | 4-Pyridoxic acid,3TBDMS,isomer #1 | CC1=NC=C(CO[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)=C1O[Si](C)(C)C(C)(C)C | 2591.1 | Semi standard non polar | 33892256 |
|
|---|
| Spectra |
|---|
| |
|---|
| Biological Properties |
|---|
| Cellular Locations | |
|---|
| Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Feces
- Saliva
- Urine
|
|---|
| Tissue Locations | - Bladder
- Erythrocyte
- Kidney
- Liver
- Placenta
|
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 0.0097 +/- 0.00665 uM | Adult (>18 years old) | Male | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 0.040 +/- 0.007 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 0.0071 +/- 0.005 uM | Adult (>18 years old) | Female | Normal | | details | | Blood | Detected and Quantified | 0.027 (0.0062-3.14) uM | Adult (>18 years old) | Both | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.00009-0.00300 uM | Children (1-13 years old) | Not Specified | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Not Specified | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Not Specified | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 0.157 +/- 0.0613 umol/mmol creatinine | Children (1 - 13 years old) | Both | Normal | | details | | Urine | Detected and Quantified | > 0.33 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 0.420 +/- 0.187 umol/mmol creatinine | Adolescent (13-18 years old) | Male | Normal | | details | | Urine | Detected and Quantified | 0.407 +/- 0.173 umol/mmol creatinine | Adolescent (13-18 years old) | Female | Normal | | details | | Urine | Detected and Quantified | 0.245 +/- 0.0873 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | > 3.0 umol/mmol creatinine | Children (1-13 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 2.99 +/- 5.25 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | | Urine | Detected and Quantified | 3.1 (0.4-7.5) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 5.975 +/- 2.873 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Normal | | details | | Urine | Detected and Quantified | 0.78 +/- 0.45 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| |
| Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal adenoma | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Crohns disease | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Iron deficiency | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Both | Crohns disease | | details | | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Both | Ulcerative colitis | | details | | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Crohns disease | | details | | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Ulcerative colitis | | details | | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Unclassified IBD | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Urine | Detected and Quantified | 1414.9 +/- 737.8 umol/mmol creatinine | Adult (>18 years old) | Both | Critically ill | | details | | Urine | Detected and Quantified | 5.701 +/- 3.878 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal adenoma | | details |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | | Crohn's disease |
|---|
- Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4. [PubMed:26848182 ]
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| | Iron deficiency |
|---|
- Lee T, Clavel T, Smirnov K, Schmidt A, Lagkouvardos I, Walker A, Lucio M, Michalke B, Schmitt-Kopplin P, Fedorak R, Haller D: Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017 May;66(5):863-871. doi: 10.1136/gutjnl-2015-309940. Epub 2016 Feb 4. [PubMed:26848182 ]
| | Colorectal cancer |
|---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| | Ulcerative colitis |
|---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| | Eosinophilic esophagitis |
|---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
|---|
| Associated OMIM IDs | |
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | FDB021874 |
|---|
| KNApSAcK ID | C00052160 |
|---|
| Chemspider ID | 6467 |
|---|
| KEGG Compound ID | C00847 |
|---|
| BioCyc ID | CPD-1112 |
|---|
| BiGG ID | 36190 |
|---|
| Wikipedia Link | Not Available |
|---|
| METLIN ID | 239 |
|---|
| PubChem Compound | 6723 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 17405 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | 4PYRDX |
|---|
| MarkerDB ID | MDB00000008 |
|---|
| Good Scents ID | rw1699441 |
|---|
| References |
|---|
| Synthesis Reference | Senkuma, Masahiko; Imada, Katsumi; Sato, Masatada. Preparation of 4-pyridoxic acid. Jpn. Kokai Tokkyo Koho (1992), 2 pp. |
|---|
| Material Safety Data Sheet (MSDS) | Download (PDF) |
|---|
| General References | - Huang YC, Lan PH, Cheng CH, Lee BJ, Kan MN: Vitamin B6 intakes and status of mechanically ventilated critically ill patients in Taiwan. Eur J Clin Nutr. 2002 May;56(5):387-92. [PubMed:12001008 ]
- Kodentsova VM, Vrzhesinskaia OA, Sokol'nikov AA, Beketova NA, Spirichev VB: [The effect of riboflavin supply on metabolism of water-soluble vitamins]. Vopr Med Khim. 1993 Sep-Oct;39(5):29-33. [PubMed:8279138 ]
- Masse PG, Mahuren JD, Tranchant C, Dosy J: B-6 vitamers and 4-pyridoxic acid in the plasma, erythrocytes, and urine of postmenopausal women. Am J Clin Nutr. 2004 Oct;80(4):946-51. [PubMed:15447904 ]
- Huang YC, Chang HH, Huang SC, Cheng CH, Lee BJ, Cheng SY, Su KH: Plasma pyridoxal 5'-phosphate is a significant indicator of immune responses in the mechanically ventilated critically ill. Nutrition. 2005 Jul-Aug;21(7-8):779-85. [PubMed:15975484 ]
- Ericson KL, Mahuren JD, Zubovic YM, Coburn SP: Use of chlorite to improve HPLC detection of pyridoxal 5'-phosphate. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):218-20. [PubMed:16054880 ]
- Driskell JA, Chrisley BM: Plasma B-6 vitamer and plasma and urinary 4-pyridoxic acid concentrations in young women as determined using high performance liquid chromatography. Biomed Chromatogr. 1991 Sep;5(5):198-201. [PubMed:1742549 ]
- Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R: Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther. 2005;7(6):R1254-62. Epub 2005 Sep 13. [PubMed:16277678 ]
- Rybak ME, Pfeiffer CM: Clinical analysis of vitamin B(6): determination of pyridoxal 5'-phosphate and 4-pyridoxic acid in human serum by reversed-phase high-performance liquid chromatography with chlorite postcolumn derivatization. Anal Biochem. 2004 Oct 15;333(2):336-44. [PubMed:15450810 ]
- Huang YC, Chang SJ, Chiu YT, Chang HH, Cheng CH: The status of plasma homocysteine and related B-vitamins in healthy young vegetarians and nonvegetarians. Eur J Nutr. 2003 Apr;42(2):84-90. [PubMed:12638029 ]
- Midttun O, Hustad S, Solheim E, Schneede J, Ueland PM: Multianalyte quantification of vitamin B6 and B2 species in the nanomolar range in human plasma by liquid chromatography-tandem mass spectrometry. Clin Chem. 2005 Jul;51(7):1206-16. [PubMed:15976101 ]
- Chang SJ, Huang YC, Hsiao LJ, Lee YC, Hsuen SY: Determination of vitamin B-6 estimated average requirement and recommended dietary allowance for children aged 7-12 years using vitamin B-6 intake, nutritional status and anthropometry. J Nutr. 2002 Oct;132(10):3130-4. [PubMed:12368406 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
|---|